Abstract
Objectives: To study the effect of antiplatelet agents on preventing arteriovenous (AV) fistulae thrombosis in hemodialysis (HD) patients after surgical thrombectomy (ST) for acute AV fistulae occlusion. Whether post-operative antiplatelet drugs have similar effects on the patency of AV fistula after surgical thrombectomy in patients with end-stage renal disease who undergo HD has not been investigated.
Design, Materials and Methods: We employed the Taiwan National Health Insurance Research Database (NHIRD) from 1999 to 2010 to assess the recurrent occlusion requiring ST and longevity of AV fistula after ST in 1049 patients on regular HD, with or without antiplatelet drugs.
Results: From the propensity-score (PS)-matched NHIRD, Multivariate Cox model demonstrated that concomitant antiplatelet medication in the HD patients who received the first ST significantly reduced the duration of recurrent ST (adjusted hazard ratio (HR) 1.69; 95% confidence interval (CI) 1.22-2.35, p=0.002) and the longevity of the fistula (adjusted HR 1.79; 95% CI 1.31-2.46, p<0.001).
Conclusion: Treatment with antiplatelet drugs in HD patients did not prevent recurrent thrombosis requiring further ST, but significantly jeopardized the longevity of AV fistula after ST.
Keywords: Antiplatelet drugs, arteriovenous fistula, thrombectomy, vascular patency.
Current Vascular Pharmacology
Title:Effects of Antiplatelet Medication on Arteriovenous Fistula Patency After Surgical Thrombectomy
Volume: 14 Issue: 4
Author(s): Chi-Hsiao Yeh, Ting-Shuo Huang, Yao-Chang Wang, Pin-Fu Huang, Tzu-Yen Huang, Tzu-Ping Chen, Shun-Ying Yin and Yu-Wei Yu
Affiliation:
Keywords: Antiplatelet drugs, arteriovenous fistula, thrombectomy, vascular patency.
Abstract: Objectives: To study the effect of antiplatelet agents on preventing arteriovenous (AV) fistulae thrombosis in hemodialysis (HD) patients after surgical thrombectomy (ST) for acute AV fistulae occlusion. Whether post-operative antiplatelet drugs have similar effects on the patency of AV fistula after surgical thrombectomy in patients with end-stage renal disease who undergo HD has not been investigated.
Design, Materials and Methods: We employed the Taiwan National Health Insurance Research Database (NHIRD) from 1999 to 2010 to assess the recurrent occlusion requiring ST and longevity of AV fistula after ST in 1049 patients on regular HD, with or without antiplatelet drugs.
Results: From the propensity-score (PS)-matched NHIRD, Multivariate Cox model demonstrated that concomitant antiplatelet medication in the HD patients who received the first ST significantly reduced the duration of recurrent ST (adjusted hazard ratio (HR) 1.69; 95% confidence interval (CI) 1.22-2.35, p=0.002) and the longevity of the fistula (adjusted HR 1.79; 95% CI 1.31-2.46, p<0.001).
Conclusion: Treatment with antiplatelet drugs in HD patients did not prevent recurrent thrombosis requiring further ST, but significantly jeopardized the longevity of AV fistula after ST.
Export Options
About this article
Cite this article as:
Yeh Chi-Hsiao, Huang Ting-Shuo, Wang Yao-Chang, Huang Pin-Fu, Huang Tzu-Yen, Chen Tzu-Ping, Yin Shun-Ying and Yu Yu-Wei, Effects of Antiplatelet Medication on Arteriovenous Fistula Patency After Surgical Thrombectomy, Current Vascular Pharmacology 2016; 14 (4) . https://dx.doi.org/10.2174/1570161114666160229115844
DOI https://dx.doi.org/10.2174/1570161114666160229115844 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Use of Peripheral Blood Stem Cells in Tissue Engineering
Current Tissue Engineering (Discontinued) The Role of Bevacizumab in Advanced Epithelial Ovarian Cancer
Current Pharmaceutical Design Technology-Dependent Children: The Chronically Ventilated Child
Current Pediatric Reviews Integrin α4β7 Antagonists: Activities, Mechanisms of Action and Therapeutic Prospects
Current Immunology Reviews (Discontinued) Defining the Cough Spectrum and Reviewing the Evidence for Treating Non-Specific Cough in Children
Current Pediatric Reviews Current Developments of Coumarin Compounds in Medicinal Chemistry
Current Pharmaceutical Design Molecular Aspects of Intestinal Radiation-Induced Fibrosis
Current Molecular Medicine Remodeling of the Myocardium and Potential Targets in the Collagen Degradation and Synthesis Pathways
Current Drug Targets - Cardiovascular & Hematological Disorders Oxidative Stress and Antioxidant Potential of One Hundred Medicinal Plants
Current Topics in Medicinal Chemistry Emerging Biologics in the Treatment of Inflammatory Bowel Disease: What is Around the Corner?
Current Drug Targets A Review on Clinical Management and Pharmacological Therapy on Hereditary Haemorrhagic Telangiectasia (HHT)
Current Vascular Pharmacology Chymase as an Important Target for Preventing Complications of Metabolic Syndrome
Current Medicinal Chemistry Advent and Maturation of Regenerative Medicine
Current Stem Cell Research & Therapy NPY Family of Hormones: Clinical Relevance and Potential Use in Gastrointestinal Disease
Current Topics in Medicinal Chemistry The Wnt/β-catenin Signalling Pathway Inhibitor Sclerostin is a Biomarker for Early Atherosclerosis in Obesity
Current Neurovascular Research The Problem of Atrial Fibrillation in Patients with Chronic Kidney Disease
Current Vascular Pharmacology The Serpin Solution; Targeting Thrombotic and Thrombolytic Serine Proteases in Inflammation
Cardiovascular & Hematological Disorders-Drug Targets Guggulsterone for Chemoprevention of Cancer
Current Pharmaceutical Design Angiogenic and Anti-Angiogenic Therapy for Gastrointestinal Ulcers: New Challenges for Rational Therapeutic Predictions and Drug Design
Current Pharmaceutical Design Gadolinium-Enhanced Magnetic Resonance Imaging, Renal Failure and Nephrogenic Systemic Fibrosis /Nephrogenic Fibrosing Dermopathy
Current Medicinal Chemistry